Scots choose chewy Lipitor but refuse Zytiga, Sycrest and Gilenya
This article was originally published in Scrip
Scotland's health technology assessment body, the Scottish Medicines Consortium, has rejected several drugs, including the first MS pill, Novartis' Gilenya and Janssen-Cilag's Zytiga (abiraterone acetate) for prostate cancer, for use on the Scottish NHS because the submitting companies failed to argue an economic case for their drugs.
You may also be interested in...
Pharmaceutical industry groups say the European Commission’s Pharmaceutical Strategy Roadmap lacks detail on delivering a faster regulatory process and encouraging competitiveness.
The Australian Therapeutic Goods Administration is consulting on a draft standard for data matrix codes on the labels of certain medicines.
The European Medicines Agency received more requests for scientific advice in 2019 than it did in 2018. Meanwhile, requests for advice in other areas has fallen.